Peptide Schedule
Romiplostim (Nplate)14 residuesIEGPTLRQWLAARAEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Romiplostim (Nplate) Dosage Calculator

ImmuneInjectionFDA Approved~3.5 days half-life

Romiplostim (Nplate) is an FDA-approved Fc-peptide fusion protein (peptibody) that acts as a thrombopoietin receptor (c-Mpl) agonist.

FDA-approved for immune thrombocytopenia (ITP) in adults and children ≥1 yearDose-dependent increase in platelet counts within 1-2 weeksReduces need for rescue therapies (IVIg, corticosteroids, transfusions)Enables reduction or discontinuation of concurrent ITP medications

1mcg · Weekly

100500
0.3 units
100 units (1mL)
Concentration
347.222
mcg/mL
Draw Volume
0.003
mL
Syringe Units
0.3
units
Doses / Vial
250
doses
Very small draw (0.3 units) — difficult to measure accurately. Consider using less BAC water for a more concentrated solution.

Summary: Add 0.72mL BAC water to your 0.25mg vial. Draw to 0.3 units on a U-100 syringe for a 1mcg dose. This vial will last 250 doses.

Cycle Planner

Subcutaneous. Typical beginner frequency: weekly.

Romiplostim (Nplate) Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~3.5 days (median)
50%25%12.5%100%75%50%25%0%04d7d11d14d18dTime after injectionDose remaining
After 1 half-life (4d): 50% remainsAfter 2 half-lives (7d): 25% remainsAfter 3 half-lives (11d): 12.5% remains
At a 3mcg dose: 50% = 2mcg remaining after 4d. Recommended frequency: Weekly.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Romiplostim (Nplate) Dosing Protocol

LevelDose / InjectionFrequency
Beginner1mcgWeekly
Moderate3mcgWeekly
Aggressive10mcgWeekly

Note: FDA-approved thrombopoietin receptor agonist (peptibody). Weight-based dosing: 1-10 mcg/kg SC weekly. Adjust by 1 mcg/kg increments to achieve platelet count ≥50 × 10⁹/L. Requires regular CBC monitoring. REMS program applies.

About Romiplostim (Nplate)

Romiplostim (Nplate) is an FDA-approved Fc-peptide fusion protein (peptibody) that acts as a thrombopoietin receptor (c-Mpl) agonist. It stimulates megakaryopoiesis and platelet production by binding to and activating the TPO receptor, mimicking the action of endogenous thrombopoietin. Approved for the treatment of immune thrombocytopenia (ITP) in adults and pediatric patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Romiplostim increases platelet counts in a dose-dependent manner, typically within 1-2 weeks of initiation.

Frequently Asked Questions